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The development of iPSCs reflected the merging of three major scientific streams and has in turn led to addi-
tional new branches of investigation. However, there is still debate about whether iPSCs are functionally
equivalent to ESCs. This question should be answered only by science, not by politics or business.Introduction
In 2006, we showed that stem cells with properties similar to
ESCs could be generated from mouse fibroblasts by simulta-
neously introducing four genes (Takahashi and Yamanaka,
2006). We designated these cells iPSCs. In 2007, we reported
that a similar approach was applicable for human fibroblasts
and that by introducing a handful of factors, human iPSCs can
be generated (Takahashi et al., 2007). On the same day, James
Thomson’s group also reported the generation of human iPSC
using a different combination of factors (Yu et al., 2007).
The Merging of Three Scientific Streams Led to the
Production of iPSCs
Like any other scientific advance, iPSC technology was estab-
lished on the basis of numerous findings by past and current
scientists in related fields. There were three major streams of
research that led us to the production of iPSCs (Figure 1). The
first stream was reprogramming by nuclear transfer. In 1962,
John Gurdon reported that his laboratory had generated
tadpoles from unfertilized eggs that had received a nucleus
from the intestinal cells of adult frogs (Gurdon, 1962). More
than three decades later, Ian Wilmut and colleagues reported
the birth of Dolly, the first mammal generated by somatic cloning
of mammary epithelial cells (Wilmut et al., 1997). These
successes in somatic cloning demonstrated that even differenti-
ated cells contain all of the genetic information that is required for
the development of entire organisms, and that oocytes contain
factors that can reprogram somatic cell nuclei. In 2001, Takashi
Tada’s group showed that ESCs also contain factors that can
reprogram somatic cells (Tada et al., 2001).
The second stream was the discovery of ‘‘master’’ transcrip-
tion factors. In 1987, a Drosophila transcription factor, Antenna-
pedia, was shown to induce the formation of legs instead of
antennae when ectopically expressed (Schneuwly et al., 1987).
In the same year, a mammalian transcription factor, MyoD,
was shown to convert fibroblasts into myocytes (Davis et al.,
1987). These results led to the concept of a ‘‘master regulator,’’
a transcription factor that determines and induces the fate of
a given lineage. Many researchers began to search for single
master regulators for various lineages. The attempts failed,
with a few exceptions (Yamanaka and Blau, 2010).
The third, and equally important, stream of research is that
involving ESCs. Since the first generation of mouse ESCs in678 Cell Stem Cell 10, June 14, 2012 ª2012 Elsevier Inc.1981 (Evans and Kaufman, 1981; Martin, 1981), Austin Smith
and others have established culture conditions that enable the
long-term maintenance of pluripotency (Smith et al., 1988). A
key factor for maintenance of mouse ESCs was leukemia inhib-
itory factor (LIF). Likewise, since the first generation of human
ESCs (Thomson et al., 1998), optimal culture conditions with
basic fibroblast growth factor (bFGF) have been established.
Combining the first two streams of research led us to hypoth-
esize that it is a combination of multiple factors in oocytes or
ESCs that reprogram somatic cells back into the embryonic
state and to design experiments to identify that combination.
Using information about the culture conditions that are needed
to culture pluripotent cells, we were then able to identify four
factors that can generate iPSCs.
Maturation and Understanding of iPSC Technology
Soon after our initial report of mouse iPSCs, other groups reca-
pitulated the factor-based reprogramming both inmice (Maherali
et al., 2007; Wernig et al., 2007) and humans (Lowry et al., 2008;
Park et al., 2008b). One of the advantages of iPSC technology
is its simplicity and reproducibility. Many laboratories began
to explore the underlying mechanisms and to modify the
procedures.
Although iPSCs can be generated reproducibly, the efficiency
of the process remains low: typically less than 1% of transfected
fibroblasts become iPSCs. This low efficiency initially raised the
possibility that iPSCs are derived from rare stem or undifferenti-
ated cells coexisting in fibroblast cultures (Yamanaka, 2009a).
Subsequent studies showed, however, that iPSCs can be
derived from terminally differentiated lymphocytes (Loh et al.,
2009) and postmitotic neurons (Kim et al., 2011a). Thus, most,
if not all, somatic cells have a potential to become iPSCs, albeit
with different efficiencies.
How then can just a small set of factors induce reprogramming
of somatic cells? It is beyond the scope of this essay to provide
an overview of the many studies that have addressed this impor-
tant question. From my perspective, the consensus of many
scientists seems to be that the reprogramming factors initiate
the reprogramming process in many more than 1% of trans-
fected cells but that the process is not completed in most of
the cells. Poorly understood stochastic events seem to be
required for full reprogramming to take place (Hanna et al.,
2009; Yamanaka, 2009a). As I discuss below, culture conditions
Figure 1. Three Scientific Streams that Led to the Development of
iPSCs
Figure 2. New Scientific Streams that Emerged from the
Development of iPSCs
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programming.
Initially iPSCswere generated using either retroviruses or lenti-
viruses, which might cause insertional mutagenesis and thus
would pose a risk for translational application and could perhaps
even lead to adverse effects like those seen in some attempts at
gene therapy (Hacein-Bey-Abina et al., 2003). Mice derived from
retrovirally derived iPSCs are apparently normal, as long as
expression of the c-Myc transgene is repressed (Aoi et al.,
2008; Nakagawa et al., 2008). However, the long-term safety of
human iPSCs cannot be guaranteed through mouse studies
alone. In addition, retroviruses may make iPSCs immunogenic
(Zhao et al., 2011). Thus, for the purpose of cell transplantation
therapy, we will need to avoid induction methods that involve
vector integration into the host genome.
Many ways to generate integration-free iPSCs have been re-
ported. These methods include plasmid (Okita et al., 2011a;
Okita et al., 2008), Sendai virus (Fusaki et al., 2009), adenovirus
(Stadtfeld et al., 2008), synthesized RNAs (Warren et al., 2010),
and proteins (Kim et al., 2009). In addition, attempts have been
made to induce reprogramming by small molecules. Among
these, plasmids and Sendai viruses are now routinely used in
many laboratories. In the Center for iPS Cell Research and Appli-
cation, Kyoto University, our favored methods are to use
episomal plasmids for regenerative medicine and either retrovi-
ruses or episomal plasmids for in vitro studies. We prefer these
methods because of their simplicity and reproducibility. Scien-
tists are now largely shifting their efforts from technology devel-
opment per se to applications.
New Scientific Streams Have Emerged from iPSC
Technology
Streams in science never cease (Figure 2). After the seminal work
in mice by Rudolf Jaenisch’s laboratory (Hanna et al., 2007),
scientists are now making progress toward using iPSCs in
regenerative medicine, for example for the treatment of Parkin-
son’s disease (Kriks et al., 2011), platelet deficiency (Takayama
et al., 2010), spinal cord injury (Nori et al., 2011; Tsuji et al.,
2010), and macular degeneration (Okamoto and Takahashi,
2011). Patient-derived iPSCs have been shown to be useful formodeling diseases and screening drug candidate libraries. Start-
ing with the seminal studies by the groups led by George Daley
(Park et al., 2008a), and Kevin Eggan (Dimos et al., 2008), more
than 100 reports published in the past three years use disease-
specific iPSCs. I was surprised that patient-specific iPSCs can
be used to recapitulate phenotypes of not only monogenic
diseases but also late-onset polygenic diseases, such as Parkin-
son’s disease (Devine et al., 2011), Alzheimer’s disease (Israel
et al., 2012; Yagi et al., 2011; Yahata et al., 2011), and schizo-
phrenia (Brennand et al., 2011). Excitement surrounds the poten-
tial for application of these cells to both analysis of disease
mechanisms and investigation of potential new treatments.
Somatic cells derived from iPSCs, particularly cardiac myocytes
and hepatocytes, could also be used for toxicology testing as an
alternative to existing approaches (Yamanaka, 2009b).
In addition, to these medical applications, iPSCs can be used
in animal biotechnology. Monkey (Liu et al., 2008), porcine (West
et al., 2010), and canine (Shimada et al., 2010) iPSCs can be
used for genetic engineering in these animals, allowing for the
generation of disease models and the production in larger
animals of useful substances, such as enzymes, that are defi-
cient in patients with genetic diseases. The technology might
potentially be useful in the future for preserving endangered
animals as well (Ben-Nun et al., 2011), althoughmany challenges
would need to be overcome. One of the most striking applica-
tions of iPSCs was reported by Nakauchi and colleagues, who
generated a rat pancreas in amouse, bymicroinjecting rat iPSCs
into mouse blastocysts deficient in a gene essential for pancreas
development (Kobayashi et al., 2010). In the future, it might
become possible to generate organs for human transplantation
using a similar strategy.
Another scientific stream that emerged from iPSC technology
is ‘‘direct reprogramming’’ from one somatic lineage to another.
As mentioned above, attempts to identify a single ‘‘master’’ tran-
scription factor have failed for most somatic lineages. However,
in light of the success of iPSC reprogramming, scientists
switched fromsearching for a single factor to looking for a combi-
nation. Melton and colleagues reported the conversion of
exocrine cells to endocrine cells in the mouse pancreas by using
a combination of three transcription factors (Zhou et al., 2008).Cell Stem Cell 10, June 14, 2012 ª2012 Elsevier Inc. 679
Table 1. Number of ESC and iPSC Clones Analyzed in Published
Studies
Conclusion about the
Relationship between
ESCs and iPSCs First Author Year
Clone
Numbers
ESC iPSC
It is difficult to distinguish
between them
A.M. Newman 2010 23 68
M.G. Guenther 2010 36 54
C. Bock 2011 20 12
There are notable
differences
M. Chin 2009 3 5
C.M. Marchetto 2009 2 2
J. Deng 2009 3 4
Z. Ghosh 2010 6 4
A. Doi 2011 3 9
Y. Ohi 2011 3 9
K. Kim 2011 6 12
R. Lister 2011 2 5
Figure 3. Overlapping Variations Present in iPSC and ESC Clones
Measurement of a range of properties of iPSCs and ESCs, including gene
expression, DNA methylation, differentiation propensity, and (for mouse cells)
complementation activity in embryos has led to the realization that the prop-
erties of both ESC and iPSC lines vary. However, as analysis of significant
numbers of clones from multiple laboratories has accumulated, it has become
clear that there is considerable overlap in terms of the properties of ESC and
iPSC lines and, at a general level, these two cell types are difficult to distin-
guish.
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of converting fibroblasts to various somatic cells, such as neural
cells (Vierbuchen et al., 2010), hepatocytes (Huang et al., 2011),
cardiac myocytes (Ieda et al., 2010), and hematopoietic progen-
itor cells (Szabo et al., 2010). Direct reprogramming is straight-
forward and rapid. One hurdle that remains is how to obtain
a sufficient amount of target cells for downstream applications.
The best usage of this new technology may be in situ direct re-
programming (Qian et al., 2012).
The Big Question: Are iPSCs Different from ESCs?
One of the most important questions regarding iPSCs is whether
they are different from ESCs and, if so, whether any differences
that do exist are functionally relevant. During the first few years of
our studies of iPSCs, we were amazed by their remarkable simi-
larity to ESCs. Starting in 2009, however, scientists started re-
porting differences between iPSCs and ESCs. For example,
Chin et al. (2009) compared three human ESC lines and five
iPSC lines by expression microarrays and identified hundreds
of genes that were differentially expressed (Chin et al., 2009).
They concluded that iPSCs should be considered a unique
subtype of pluripotent cells. Two other studies also compared
the global gene expression between ESCs and iPSCs and iden-
tified persistent donor cell gene expression in iPSCs (Ghosh
et al., 2010; Marchetto et al., 2009).
It was Deng et al. (2009) who first reported that there were
differences in DNA methylation between the two types of plurip-
otent stem cell lines after they performed the targeted bisulfite
sequencing of three human ESC clones and four iPSCs lines.
Doi et al. (2009) also reported that there were differentially meth-
ylated genes, such as BMP3, between ESCs and iPSCs. Subse-
quently, three studies reported epigenetic memories of donor
cells in human induced pluripotent cells (Kim et al., 2011b; Lister
et al., 2011; Ohi et al., 2011).
However, other studies have concluded that it is difficult to
distinguish iPSCs from ESCs by gene expression or DNA meth-
ylation. Two reports showed that both iPSC clones and ESC
clones have overlapping variations in gene expression and
thus that the two types of pluripotent stem cells are clustered680 Cell Stem Cell 10, June 14, 2012 ª2012 Elsevier Inc.together by these analyses (Guenther et al., 2010; Newman
and Cooper, 2010). They argued that these variations are, at
least in part, derived from the different induction and culture
conditions used by each laboratory. Bock et al. (2011) demon-
strated that iPSCs and ESCs are very similar in their gene
expression and DNA methylation and that some iPSC clones
cannot be distinguished from ESCs. By examining how many
iPS and ES clones were compared, we observed a clear
tendency (Table 1). Studies that reported differences either
in gene expression or DNA methylation compared relatively
small numbers (generally fewer than 10) for each group),
whereas those that found it difficult to distinguish iPSCs from
ESCs analyzed many more clones, and clones from multiple
laboratories.
Another major point of discussion has been the ability of the
cells to differentiate and whether iPSCs are functionally different
from ESCs in this respect. Hu et al. (2010) performed in vitro
directed neural differentiation of five human ESC clones and 12
iPSCs clones. They showed that all of the ESC clones differenti-
ated intoPax6positive cells,withmore than90%efficacy, but the
iPSC clones showed poorer differentiation, with 10% to 50%
efficacy. However, Boulting et al. (2011) examined 16 human
iPSC clones for their ability to differentiate into motor neurons
and found that 13 of these iPSC clones differentiated with
comparable efficacies to ESCs. So, again, there are conflicting
conclusions regarding the similarity between iPSCs and ESCs.
Taken together, these studies showed that iPSC clones and
ESC clones have overlapping degrees of variation (Figure 3). It
should be noted that variations among ESC clones have been
well documented (Osafune et al., 2008; Ward et al., 2004).
Although it is possible that iPSC clones show greater variation,
and that some clones differ from ESCs in their gene expression,
DNA methylation, or differentiation ability (Miura et al., 2009), it
appears that at least some iPSC clones are indistinguishable
from ESC clones.
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between the iPSC clones. We learned an important lesson
from two related reports regarding mouse iPSCs (Carey et al.,
2011; Stadtfeld et al., 2010). These two studies, conducted in
the Hochedlinger lab and the Jaenisch lab, used very similar
secondary induction systems to generate mouse iPSCs.
However, the properties of the iPSC clones were very different
between the two laboratories. Most of the iPSC clones gener-
ated in Hochedlinger lab could not be successfully used to
generate germline competent chimeras by microinjection or
‘‘all-iPSC’’ mice by tetraploid complementation, the most strin-
gent criterion to evaluate pluripotency. They showed that the
loss of imprinting of the Dlk1-Dio3 gene cluster predicts these
poor iPSC abilities. In sharp contrast, most of the iPSC clones
generated in the Jaenisch laboratory had normal imprinting of
the Dl1-Dios3 cluster and were capable of generating high
quality chimeras and viable all-iPSC mice.
The only notable difference between the two laboratories’
methods was the order of the reprogramming factors in the
expression cassettes, and this difference resulted in higher
expression levels of Oct4 and Klf4 in the cells generated by the
Jaenisch laboratory. By increasing the expression of Oct4 and
Klf4 (Carey et al., 2011), or by supplementing with ascorbic
acid (Stadtfeld et al., 2012), the quality of the iPSCs generated
by an otherwise very similar method was enhanced. Thus, the
level and stoichiometry of the reprogramming factors, as well
as culture conditions, during iPSC generation can contribute
significantly to the variation seen in the epigenetic state and
pluripotent potential of the resulting iPSCs.
These data demonstrated that incomplete or imperfect re-
programming is not a fundamental problem associated with
iPSCs. Instead, differences in the quality of iPSC clones seem
to be largely due to technical variables, such as the factor combi-
nations, gene delivery methods, and culture conditions. In addi-
tion, some variation between iPSC clones can be attributed to
stochastic events during reprogramming, which cannot be
controlled. Thus, evaluation and selection will be essential for
identifying iPSC clones that are suitable for medical applications.
Is There a ‘‘Dark Side’’ to Induced Pluripotency?
Several reports have suggested that, in addition to variation in
gene expression, DNA methylation, and pluripotent potential,
there are other potential abnormalities in iPSCs, including
somatic mutations (Gore et al., 2011), copy number variations
(Hussein et al., 2011), and immunogenicity (Zhao et al., 2011).
In some of these reports, the negative aspects of iPSCs were,
in my opinion, overstated. The media overreacted, as did
accompanying scientific commentaries with alarming words in
their titles, such as ‘‘dark side,’’ ‘‘under attack,’’ ‘‘flaw,’’ ‘‘trouble-
some,’’ and ‘‘growing pains’’ (Apostolou and Hochedlinger,
2011; Dolgin, 2011; Hayden, 2011; Pera, 2011; Zwaka, 2010).
However, despite these doomsday headlines, subsequent
analyses have indicated that many of the genetic differences
found in iPSCs seem to have pre-existed in the original somatic
cells, and therefore arose independently of the reprogramming
process itself (Cheng et al., 2012; Young et al., 2012). Reprog-
ramming to form iPSCs is inherently clonal, and therefore varia-
tions that exist at a low frequency within the starting cell popula-
tion can become more apparent when analyzing individualclones derived from it and comparing them to the parental cell
population as a whole.
Another study showed that a set of iPSC clones that are
capable of generating all-iPSC mice have very few genetic alter-
ations relative to their parental cells (Quinlan et al., 2011). The
chimeric and progeny mice derived from iPSCs that are devoid
of the Myc transgene appear to be normal, indicating that these
iPSCs do not contain detrimental genetic alterations that have
a negative impact on function (Nakagawa et al., 2008; Nakagawa
et al., 2010). With regard to immunogenicity, it is not clear
whether the reported weak immune reaction to transgene-free
iPSCs is significant (Okita et al., 2011b) because the most prom-
inent study that reported the immunogenicity of the cells exam-
ined undifferentiated iPSCs (Zhao et al., 2011), which will never
be used in cell transplantation therapy. We have to understand
all of these results and consider them in context to have
a balanced view of iPSCs.
Why Are ESCs and iPSCs So Remarkably Similar?
Although there may be some differences between iPSCs and
ESCs, they are, nevertheless, remarkably similar. If anything,
we should perhaps be wondering why iPSCs and ESCs are in
fact so similar despite their different origins and generation
methods. No other examples of this level of similarity between
man-made cells and naturally-existing cells exist. Several types
of somatic cells, such as neural cells and cardiacmyocytes, have
been generated from ESCs/iPSCs or directly from fibroblasts.
These man-made somatic cells have some of the characteristics
of their normal counterparts that exist in vivo, but they are still
very different from natural neural cells and cardiac myocytes.
The similarity between ESCs and iPSCs is therefore in many
ways exceptional.
One potential explanation is that ESCs are in fact also man-
made. It is possible that ESCs do not exist under physiological
conditions and instead are selected and established by culti-
vating the cells of the inner cell mass (ICM) under specific culture
conditions. ESCs are different from the majority of cells in the
ICM in many respects. For example, although cells in the ICM
possess a low degree of global DNA methylation (Reik et al.,
2001), ESCs have a higher level of methylation (Li et al., 1992).
A Ras family gene, ERas, is highly expressed in mouse ESCs
but not in embryos (Takahashi et al., 2003). ESCs also have
longer telomeres than are seen in embryos (Varela et al., 2011).
Thus, we may be discussing the relationship between two types
of man-made cells rather than between man-made cells and
naturally existing cells.
Through many researchers’ efforts, the field has established
culture conditions that enable the generation and long-term
maintenance of both mouse and human ESCs. It is likely that
these culture conditions select for cells with certain properties,
and this selection would also contribute to making ESCs and
iPSCs appear as similar as they do.
Concluding Thoughts
If we accept the idea that ESCs and iPSCs are both artificial cells
types generated in the laboratory, we move on to another impor-
tant question: do ESCs truly represent an ultimate control or gold
standard for iPSCs? I think the answer is probably no. Instead,
future studies should focus on the capacity of iPSCs themselvesCell Stem Cell 10, June 14, 2012 ª2012 Elsevier Inc. 681
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that exists in parallel to that of ESCs as a branch of the same
overall experimental river.
I believe that iPSC technology is now ready for many applica-
tions, including stem cell therapies. From each induction proce-
dure, multiple iPSC clones of various qualities emerged
(Figure 3). It is thus essential to select good clones for medical
applications. We may be able to narrow down candidates for
good clones by marker gene expressions. However, we have
to confirm in vitro differentiation propensities and genome and
epigenome integrities. For wide-spread use, it might be neces-
sary to establish in advance stocks of qualified iPSC clones
from healthy volunteers or from cord-blood stocks. Immunore-
jection could be decreased by generating iPSCs from HLA
homozygous donors (Okita et al., 2011a).
iPSC technology will likely have a substantial impact not only
on science but also on business and politics. However, iPSCs
should be evaluated based strictly on the scientific data, and
all such data should be thoroughly considered for its relevance
to potential clinical applications of the cells. Scientists should
focus on research, and politicians and businesses should rely
on the hard evidence generated from scientific studies to inform
future directions rather than on the opinions of those who do not
fully understand the field.
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